MedTrace Logo

Pharmacokinetics and Safety of ALA in Acne Vulgaris

NCT04044898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2022-03-17

No results posted yet for this study

Summary

This study will evaluate the pharmacokinetics and safety of ALA in patients with moderate and severe acne vulgaris after single dose in different dosages.

Conditions

  • Acne Vulgaris

Interventions

DRUG

ALA 5%

prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose

DRUG

ALA 10%

prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose

Sponsors & Collaborators

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2021-07-30
Completion
2021-12-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04044898 on ClinicalTrials.gov